121
Participants
Start Date
November 29, 2011
Primary Completion Date
August 7, 2016
Study Completion Date
August 7, 2016
Etrolizumab
Participants will receive etrolizumab at a dose of 100 mg.
ENDOMEDIX Kft; Gasztroenterológia Budapest, Budapest
Pannónia Klinika Magánorvosi, Budapest
The Canberra Hospital, Garran
Imeldaziekenhuis, Bonheiden
UZ Leuven Gasthuisberg, Leuven
Alfred Hospital, Melbourne
Royal Melbourne Hospital; Gastroenterology, Parkville
St Vincent's Hospital Melbourne; Department of Gastroenterology, Fitzroy
University of Otago, Christchurch, Christchurch
UZ Gent, Ghent
Petz Aladar County Hosp; 1St Dept. of Internal Med., Győr
Dunedin Hospital; Otago District Health Board, Dunedin
Long Island Clin Rsch Asc, LLP, Great Neck
CAMPUS VIRCHOW-KLINIKUM; Charité Centrum 13; Med. Klinik Abt. Hepatologie u. Gastroenterologie, Berlin
Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel
Atlanta Gastroenterology Associates, Atlanta
Med. Hochschule Hannover; Gastroenterologie, Hanover
Facharzt für Gastroenterologie, Minden
Consultants for Clin. Rsrch, Cincinnati
Mayo Clinic Cancer Center, Rochester
Univ klinikum Ulm; Medizin Zentrum Innere Medizin I, Ulm
University of California, San Diego, La Jolla
Rambam Medical Center, Haifa
The Chaim Sheba Medical Center; Multiple Sclerosis Center, Ramat Gan
Tel Aviv Sourasky Medical Ctr; Gastroenterology Department, Tel Aviv
Shaare Zedek Medical Center, Jerusalem
Shaare Zedek Medical Ctr; Dept. of Gastroenterology, Jerusalem
GI Research Institute, Vancouver
London Health Sciences Centre; Victoria Hospital, London
London Health Sciences Centre, London
Toronto Digest. Disease Asso., Woodbridge
Poliklinika Iii, Hk; Hepatogatroenterolgy, Hradec Králové
Oblastni nemocnice Nachod a.s.; Endoskopicke centrum, Náchod
Fakultni nemocnice Ostrava, Ostrava - Poruba
Krajska nemocnice Tomase Bati, Zlín
Middlemore Hospital, Auckland
Shakespeare Specialist Group, Takapuna
Hospital Clinic I Provincial, Barcelona
St. Mark's Hospital; Inflammatory Bowel Disease Unit, Harrow
Royal Victoria Infirmary, Newcastle upon Tyne
Lead Sponsor
Genentech, Inc.
INDUSTRY